

SYNTHESIS AND CRYSTAL STRUCTURE OF SOME 3,5-PYRAZOLIDINEDIONES

Saoud A. M. Metwally^{1*}, Maisa I. Abdel Moneim¹, Yasser A. Elossely¹,
Radwa I. Awad², Khaled Abou-Hadeed³

Syntheses of various derivatives of 3,5-pyrazolidinedione are reported. This includes 4-arylidene (alkylidene or aralkylidene)-3,5-pyrazolidinediones, which on epoxidation gave unreported oxiranes. The syntheses of these derivatives were based on either the Knoevenagel reaction of carbonyl derivatives with 3,4-pyrazolidinedione or cyclization of arylidene (alkylidene) malonic acid hydrazide with glacial acetic acid. 4-Arylazo-3,5-pyrazolidinedione derivatives were also prepared by coupling of aryl diazonium salts with 3,5-pyrazolidinedione or cyclization of arylazomalonic acid hydrazide. Reduction of 4-benzylidene derivatives gave the corresponding benzyl derivatives. The structure of the new products was confirmed by elemental and spectral analyses and X-ray crystallography.

Keywords: 3,5-pyrazolidinediones, X-ray crystallography.

Historically, dyes and pharmaceuticals derived from pyrazolinones were among the first successful commercial synthetic organic chemicals in which interest has continued actively until the present day. Research in this field has culminated in the discovery of the useful anti-inflammatory properties of 4-*n*-butyl-1,2-diphenyl-3,5-pyrazolidinedione (phenylbutazone) [1]. In spite of the problems encountered in the undesirable side reactions, principally agranulocytosis produced by these drugs [2-7], interest in them has never abated and one feels confident in predicting the discovery of additional useful and improved drugs in this class of compounds [8-10]. The development of new and improved dyes based on pyrazolinone structures has likewise led to modern developments of no inconsiderable magnitude. The use of tetrazine [11-14] as an approved color for foodstuffs is of significance. The synthesis of pyrazolidinedione dyes for use as magenta couplers and sensitizers in color photography has been suggested [15, 16]. Metal chelate pyrazolidinone dye structures have caused a renewed interest in the use of these dyes in analytical procedures [17-19]. Recently 3,5-pyrazolidinediones have found extensive applications in veterinary medicine [20-34].


* To whom correspondence should be addressed, e-mail: Saoudmetwally@hotmail.com.

¹Chemistry Department, Assiut University, Egypt.

²Forensic Medicine Laboratories, Assiut, Egypt.


³Institute of Organic Chemistry, University of Zurich, Switzerland.

The aim of this work is the synthesis of 3,5-pyrazolidenedione derivatives **6** starting from the unsubstituted 3,5-pyrazolidenedione (**5**) or malonic acid hydrazide derivatives **8** and **15**. As an important starting material in this work, 3,5-pyrazolidenedione (**5**) was prepared according to [35] *via* cyclization of ethoxycarbonylaceto-hydrazide (**3**) [36] using sodium methoxide. Condensation of compound **5** with aliphatic or aromatic carbonyl derivatives gave the corresponding 4-alkylidene(arylidene)- or (aralkylidene)-3,5-pyrazolidenediones **6**.



6 a $R = R^1 = \text{Me}$; **b** $R = \text{H}$, $R^1 = p\text{-BrC}_6\text{H}_4$, **c** $R^1 = p\text{-ClC}_6\text{H}_4$, **d** $R^1 = p\text{-OHC}_6\text{H}_4$,
e $R^1 = p\text{-Me}_2\text{NC}_6\text{H}_3$, **f** $R^1 = p\text{-MeC}_6\text{H}_4$, **g** $R + R^1 = 4\text{-(indoxyl-3-yl)}$

On the other hand, cyclization of alkylidene- or arylidenemalonic acid hydrazides **8** using glacial acetic acid yielded 1-acetyl-4-alkylidene(arylidene)-3,5-pyrazolidenediones **9**.



9 a $R = \text{H}$, $R^1 = o\text{-O}_2\text{NC}_6\text{H}_4$; **b** $R = R^1 = \text{isopropylidene}$;
ch $R = \text{H}$, **c** $R^1 = p\text{-MeC}_6\text{H}_4$, **d** $R^1 = p\text{-Me}_2\text{NC}_6\text{H}_3$, **e** $R^1 = p\text{-ClC}_6\text{H}_4$,
f $R^1 = p\text{-O}_2\text{NC}_6\text{H}_4$, **g** $R^1 = m\text{-O}_2\text{NC}_6\text{H}_4$, **h** $R^1 = p\text{-HOC}_6\text{H}_4$





Fig. 1. The chemical structure of compounds **6a** (a), **6e** (b), and **10** (c)


The structure of 4-substituted 3,5-pyrazolidinediones **6** and 1-acetyl derivatives **9** [37] was determined using elemental analysis and spectroscopic methods.

Epoxidation of some 4-alkylidene or arylidene-3,5-pyrazolidinediones **6a,e** using alkaline hydrogen peroxide in ether [38] yielded the unreported oxirane derivatives **10** and **11**.



The chemical structure of compounds **6a,e** and **10** has been solved and refined successfully using X-ray crystallography (Fig. 1a–c). Both ring N-atoms showed a slight pyramidalization in compound **6a** and significant pyramidalization in compounds **6e** and **10** and particularly at N(2), rather than the usual planar arrangement common in amides. This is probably due to preferential delocalization of the C=O bonds with the C(4)=C(6) bond. The phenyl ring and C(10)–N(13) bonds showed a slight trend towards a quinoline type double bond localization, but the effect is very small. The X-ray structure of compound **6a** indicated that one amide group forms an intermolecular hydrogen bond with the O-atom of the same amide group of an adjacent molecule, thereby linking pairs of molecules into centrosymmetric dimers. The other amide group forms bifurcated intermolecular hydrogen bonds. The combination of these interactions creates a two-dimensional network. See Table 1 for full details.

A series of 4-aryloxy-3,5-pyrazolidinediones **13** was prepared either by coupling aryl diazonium salts **12** with compound **5** or cyclization of arylazomalonic acid hydrazide **15** using acetic acid to give 1-acetyl-4-aryloxy-3,5-pyrazolidinedione derivatives **16**.



13 a Ar = Ph, **b** Ar = *p*-MeOC₆H₄; **13c, 14a–16a** Ar = O₂NC₆H₄;
13d, 14b–16b Ar = *o*-ClC₆H₄

The structure of 4-aryloxy-3,5-pyrazolidinedione **13** or its 1-acetyl derivatives **16** was confirmed using elemental analysis and spectroscopic methods.

The exocyclic double bond at position 4 of compounds **6e** and **9f** was smoothly reduced to the corresponding single bond using sodium borohydride in methanol [39], yielding the corresponding 4-benzyl derivatives **17** and **18**, respectively.





TABLE 1. Crystallographic Data

	6a	6c	10
Crystallized from	MeOH	DMF/H ₂ O	MeOH
Empirical formula	C ₆ H ₈ N ₂ O ₂	C ₁₂ H ₁₃ N ₃ O ₂	C ₆ H ₈ N ₂ O ₃
Formula weight, g·mol ⁻¹	140.14	231.25	156.14
Crystal color, habit	Yellow, plate	Red, prism	Colorless, plate
Crystal dimensions, mm	0.07×0.20×0.25	0.12×0.20×0.20	0.07×0.22×0.25
Temperature, K	160(1)	160(1)	160(1)
Crystal system	Monoclinic	Triclinic	Orthorhombic
Space group	<i>P</i> 2 ₁ / <i>c</i>	<i>P</i> 1	<i>Pbca</i>
<i>Z</i>	4	2	8
Reflections for cell determination	1211	2923	2299
2θ range for cell determination, deg	4-50	4-60	4-60
Unit cell parameters			
<i>a</i> , Å	7.5852(3)	6.0986(4)	11.2797(3)
<i>b</i> , Å	6.8324(5)	7.9152(5)	8.5218(2)
<i>c</i> , Å	12.5924(7)	11.4088(6)	14.3066(3)
α, deg	90	100.815(4)	90
β, deg	104.773(4)	94.040(4)	90
γ, deg	90	102.145(3)	90
<i>V</i> , Å ³	631.03(6)	525.36(6)	1375.20(6)
<i>F</i> (000)	296	244	656
<i>D_s</i> , g·cm ⁻³	1.475	1.462	1.508
μ(MoKα), mm ⁻¹	0.113	0.103	0.122
Scan type	φ and ω	φ and ω	φ and ω
2θ _{max} , deg	50	60	60
Total reflections measured	9933	13 664	23 769
Symmetry-independent reflections	1111	3059	2002
<i>R</i> _{int}	0.063	0.047	0.056
Reflections with <i>I</i> < 2σ(<i>I</i>)	932	2232	1613
Reflections used in refinement	1110	3059	2002
Parameters refined	101	164	111
<i>R</i> (<i>F</i>) [<i>I</i> < 2σ(<i>I</i>) reflections]	0.0430	0.0549	0.0403
<i>wR</i> (<i>F</i> ²) (all independent reflections)	0.1144	0.1547	0.1078
Weighting parameters [a;b]*	0.062; 0.164	0.0818; 0.1463	0.0505; 0.293
<i>GOOF</i>	1.067	1.028	1.064
Secondary extinction coefficient	—	—	0.015(3)
Final Δ _{max} /σ	0.001	0.001	0.001
Δρ (max, min), e Å ⁻³	0.16; -0.23	0.33; -0.33	0.29; -0.23

* $w^{-1} = \sigma^2(F_o^2) + (aP)^2 + bP$, where $P = (F_o^2 + 2F_c^2)/3$.

EXPERIMENTAL

IR spectra were determined on a Shimadzu 480 IR spectrophotometer using the KBr pellet technique. ¹H and ¹³C NMR spectra were recorded on a JEOL LA 400 NMR spectrometer (400 and 100 MHz respectively),

solvent DMSO- d_6 , internal standard TMS. The mass spectra were obtained on a JEOL route-600 H spectrometer using the direct inlet technique at 70 eV. All melting points were determined on an electric melting point apparatus (Gallenkamp) and are uncorrected. Elemental analyses were carried out by the microanalytical unit at Chemistry Department, Assiut University, using an Elementar Vario EI elemental analyzer.

Ethoxycarbonylaceto-hydrazide (3). The following is an improved preparation method [36]. Hydrazine hydrate (6.0 g, 0.187 mol) was added at room temperature to a solution of diethyl malonate (50 g, 0.312 mol) in ethanol (20 ml). The mixture was stored overnight, and malonohydrazide (**4**) (3.9 g) was separated by filtration, mp 151-153°C (154°C [40]). Evaporation of the filtrate left a partly crystalline residue, which was washed with ether to remove the unchanged ester. The solid ethoxycarbonylaceto-hydrazide was recrystallized twice from ethanol. Yield 7.5 g; mp 68-69°C (70°C [36]). The experiment was repeated twice with the recovered diethyl malonate; each time 0.3 mol of hydrazine hydrate was used. Total yield 15.5 g (34%) based on the original 50 g of diethyl malonate (8% [41]). IR spectrum, ν , cm^{-1} : 3300, 3040 (NH₂, NH), 1725, 1645 (C=O). ¹H NMR spectrum, δ , ppm (*J*, Hz): 1.16 (3H, t, *J* = 7.1, CH₃); 3.13 (2H, s, CH₂); 4.05 (2H, q, *J* = 7.1, CH₂); 9.10 (1H, s, NH). ¹³C NMR, δ , ppm: 14.05 (CH₃); 38.80 (CH₂); 164 (C=O). Mass spectrum, *m/z* (*I*_{rel.}, %): 146 [M]⁺ (42), 115 (14), 101 (65), 100 (72), 87 (32), 69 (18), 60 (14), 59 (20), 58 (20), 32 (100). Found, %: C 41.18; H 6.84; N 19.21. C₅H₁₀N₂O₃. Calculated, %: C 41.09; H 6.90; N 19.17.

Malonohydrazide (4). Colorless flakes from ethanol. Yield 3.9 g (4.7%); mp 151-153°C (154°C [40]). IR spectrum, ν , cm^{-1} : 3295-3100 (NH₂, NH), 1640 (C=O). ¹H NMR spectrum, δ , ppm (*J*, Hz): 3.41 (2H, s, CH₂); 9.06 (1H, s, NH); 10.32 (2H, s, NH). Mass spectrum, *m/z* (*I*_{rel.}, %): 132 [M]⁺ (35), 131 (25), 100 (84), 99 (74), 74 (18), 69 (58), 59 (72), 45 (17), 44 (94), 43 (88), 42 (70), 33 (68), 32 (100). Found, %: C 27.31; H 6.12; N 42.32. C₃H₈N₄O₂. Calculated, %: C 27.27; H 6.10; N 42.41.

3,5-Pyrazolidinedione (5). A solution of sodium methoxide (0.7 g sodium dissolved in 10 ml dry methanol) was added dropwise during 4-5 h to a cold solution of ethoxycarbonylaceto-hydrazide **3** (5 g dissolved in 35 ml dry methanol). The mixture was left in a refrigerator for 24 h, then filtered off, and the filtrate was cooled to -15°C and neutralized with glacial acetic acid (3.4 ml). The precipitated crystals were collected by filtration, washed with cold methanol, and dried. Colorless needles from methanol, 2.38 g, 70%; mp 290°C (decomp) (290°C [35]). IR spectrum, ν , cm^{-1} : 2995, 2720 (broad, NH, OH), 1655 (C=O). ¹H NMR spectrum, δ , ppm: 3.03 (2H, s, CH₂); 10.31 (2H, br. s, 2NH). ¹³C NMR spectrum, δ , ppm: 40.05 (CH); 169.20 (C=O). Mass spectrum, *m/z* (*I*_{rel.}, %): 100 [M]⁺ (100). Found, %: C 35.99; H 3.99; N 27.92. C₃H₄N₂O₂. Calculated, %: C 36.01; H 4.03; N 27.99.

Reaction of 3,5-Pyrazolidinedione (5) with Carbonyl Derivatives (General Method). A mixture of equimolar amounts of compound **5** and the selected carbonyl reagent (aldehyde or ketone) in pure methanol was refluxed for 30 min. After cooling, the precipitated product was collected and crystallized from the proper solvent and identified as a 4-alkylidene(arylidene)-3,5-pyrazolidinedione **6**.

4-Isopropylidene-3,5-pyrazolidinedione (6a). Yellow plates from methanol. Yield 76%; mp 238-239°C. IR spectrum, ν , cm^{-1} : 3290 (NH), 1650 (C=O). ¹H NMR spectrum, δ , ppm: 2.41 (6H, s, CH₂); 7.82 (2H, br. s, 2NH). ¹³C NMR spectrum, δ , ppm: 22.16 (CH₃), 23.19 (CH₃), 136.92 (C-6); 160.10 (C-4); 166.92 (C-3); 173.91 (C-5). Mass spectrum, *m/z* (*I*_{rel.}, %): 140 [M]⁺ (81), 125 (64), 123 (66), 109 (50), 97 (44), 83 (35), 82 (75), 72 (42), 67 (100). Found, %: C 51.36; H 5.81; N 19.87. C₆H₈N₂O₂. Calculated, %: C 51.42; H 5.75; N 19.99.

4-(4'-Bromobenzylidene)-3,5-pyrazolidinedione (6b). Dark-yellow flakes from ethanol. Yield 86%; mp 160°C. IR spectrum, ν , cm^{-1} : 3210 (NH), 1690 (C=O). ¹H NMR spectrum, δ , ppm: 7.12-7.82 (4H, m, Ar); 8.61 (1H, s, =CH); 9.90 (2H, s, 2NH). ¹³C NMR spectrum, δ , ppm: 115.1, 117.1, 119.3, 124.3, 172.2, 185.1. Mass spectrum, *m/z* (*I*_{rel.}, %): 265 [M]⁺ (58), 239 (42), 237 (38), 210 (90), 208 (100), 182 (32), 181 (36), 103 (55), 102 (52), 101 (28), 90 (31), 89 (63). Found, %: C 44.82; H 2.75; Br 29.63; N 10.43. C₁₀H₇BrN₂O₂. Calculated, %: C 44.97; H 2.64; Br 29.92; N 10.49.

4-(4'-Chlorobenzylidene)-3,5-pyrazolidinedione (6c). Colorless needles from ethanol. Yield 63%; mp 176-177°C. IR spectrum, ν , cm^{-1} : 3200 (NH); 1680 (C=O). ¹H NMR spectrum, δ , ppm: 7.53-8.20 (4H, m, Ar); 8.69 (1H, s, =CH); 11.83 (2H, br. s, 2NH). ¹³C NMR spectrum, δ , ppm: 116, 118, 122.1, 126.3, 132.1, 136.2,

138.1, 162.1, 174.4. Mass spectrum, m/z (I_{rel} , %): 222 [M]⁺ (93), 178 (14), 165 (100), 153 (60), 139 (66), 138 (80), 136 (80). Found, %: C 45.53; H 3.11; Cl 14.78; N 23.52. C₉H₇ClN₄O₂. Calculated, %: C 45.30; H 2.96; Cl 14.86; N 23.48.

4-(4'-Hydroxybenzylidene)-3,5-pyrazolidinedione (6d). Grayish needles from ethanol. Yield 80%; mp 260-261°C. IR spectrum, ν , cm⁻¹: 3100 (NH), 1650 (C=O). ¹H NMR spectrum, δ , ppm: 7.53–7.93 (4H, m, Ar); 8.69 (1H, s, =CH); 11.83 (2H, br. s, 2NH). ¹³C NMR spectrum, δ , ppm: 116, 118, 119, 122.2, 126.1, 130.1, 132.2, 162.1, 174.3. Mass spectrum, m/z (I_{rel} , %): 204 [M]⁺ (100), 203 (9), 146 (98), 136 (27.4), 120 (8), 119 (18), 118 (100). Found, %: C 58.66; H 4.11; N 13.69. C₁₀H₈N₂O₃. Calculated, %: C 58.82; H 3.95; N 13.72.

4-(4'-N,N-Dimethylaminobenzylidene)-3,5-pyrazolidinedione (6e). Red prisms from DMF–H₂O, 1:1. Yield 86%; mp 266-267°C. IR spectrum, ν , cm⁻¹: 3450 (OH or NH), 1690 (C=O). ¹H NMR spectrum, δ , ppm: 3.06 (6H, s, 2CH₃); 6.74-8.10 (4H, m, Ar); 8.53 (1H, s, =CH); 9.22 (2H, br. s, 2NH). ¹³C NMR spectrum, δ , ppm: 39.5 (2CH₃), 117.3, 119.2, 132.1, 140.3, 164.2, 171.2. Mass spectrum, m/z (I_{rel} , %): 231 [M]⁺ (100), 230 (32), 202 (4), 163 (7.3), 147 (5.2), 146 (12), 145 (24), 173 (78). Found, %: C 62.46; H 5.73; N 18.24. C₁₂H₁₃N₃O₂. Calculated, %: C 62.33; H 5.67; N 18.17.

4-(4'-Methylbenzylidene)-3,5-pyrazolidinedione (6f). Colorless needles from ethanol. Yield 58%; mp 269-270°C. IR spectrum, ν , cm⁻¹: 3100 (NH), 1655 (C=O). ¹H NMR spectrum, δ , ppm: 2.52 (3H, s, CH₃); 7.41-7.65 (4H, m, Ar); 8.21 (1H, s, CH); 9.72 (2H, br. s, 2NH). ¹³C NMR spectrum, δ , ppm: 40.0 (CH₃); 118.1, 121.1, 132.3, 135.0, 162.3, 174.2 (C=O). Mass spectrum, m/z (I_{rel} , %): 202 [M]⁺ (100), 187 (50), 174 (32), 146 (21), 113 (46). Found, %: C 65.42; H 5.02; N 13.76. C₁₁H₁₀N₂O₂. Calculated, %: C 65.34; H 4.98; N 13.85.

4-(Indoxyl-3-yl)-3,5-pyrazolidinedione (6g). Dark-grey needles from methanol. Yield 82%; mp 209-210°C. IR spectrum, ν , cm⁻¹: 3450, 3250 (OH, NH), 1680 (C=O). ¹H NMR spectrum, δ , ppm: multiplet, 7.35-7.62 (4H, m, Ar); 9.82 (2H, br. s, 3NH). ¹³C NMR spectrum, δ , ppm: 118.1, 119.1, 121.3, 129.1, 142.2, 165.1, 172.1. Mass spectrum, m/z (I_{rel} , %): 229 [M]⁺ (100). Found, %: C 57.72; H 3.21; N 18.45. C₁₁H₇N₃O₃. Calculated, %: C 57.65; H 3.08; N 18.33.

1-Acetyl-4-(2'-nitrobenzylidene)-3,5-pyrazolidinedione (9a). This derivative was prepared by fusion of equimolar amounts of *o*-nitrobenzaldehyde and compound **5** in the presence of a few drops of acetic anhydride for 5 min. The melt was cooled and triturated with ether. The solid was collected by filtration and crystallized from ethanol. Yield 86%; mp 181-182°C. IR spectrum, ν , cm⁻¹: 3200, 3100 (NH), 1640 (C=O). ¹H NMR spectrum, δ , ppm: 2.37 (3H, s, COCH₃), 7.92-8.31 (4H, m, Ar); 8.40 (1H, s, CH); 10.21 (1H, s, NH). ¹³C NMR spectrum, δ , ppm: 22.1 (CH₃); 123.4, 127.2, 176.1. Mass spectrum, m/z (I_{rel} , %): 233 [M]⁺ (100), 203 (2), 149 (4), 148 (3), 147 (1). Found, %: C 52.85; H 3.42; N 15.32. C₁₂H₉N₃O₅. Calculated, %: C 52.37; H 3.30; N 15.27.

Synthesis of 1-Acetyl-4-alkylidene(arylidene)-3,5-pyrazolidinediones **9 from Malonohydrazide **4** and Carbonyl Derivatives **9** (General Method).** A mixture of equimolar amounts of malonohydrazide **4** and the proper aldehyde or ketone dissolved in glacial acetic acid was refluxed for 30 min. The precipitated product on cooling was collected and crystallized from the proper solvent. All products were characterized as 1-acetyl-4-substituted 3,5-pyrazolidinediones **9** [37].

1-Acetyl-4-isopropylidene-3,5-pyrazolidinedione (9b). Yellow needles from methanol. Yield 75%; mp 252-253°C. IR spectrum, ν , cm⁻¹: 3200 (NH), 1710, 1680 (C=O). ¹H NMR spectrum, δ , ppm: 2.38 (6H, s, 2CH₃); 2.52 (3H, s, COCH₃); 9.21 (1H, s, NH). ¹³C NMR spectrum, δ , ppm: 118.2, 165.2, 171.5. Mass spectrum, m/z (I_{rel} , %): 182 [M]⁺ (42), 140 (100), 125 (40), 115 (7), 92 (11), 89 (14), 75 (13), 43 (99). Found, %: C 52.68; H 5.62; N 15.22. C₈H₁₀N₂O₃. Calculated, %: C 52.74; H 5.53; N 15.38.

1-Acetyl-4-(4'-methoxybenzylidene)-3,5-pyrazolidinedione (9c). Colorless needles from methanol. Yield 63%; mp 200-201°C. IR spectrum, ν , cm⁻¹: 3150 (NH), 1720, 1675 (C=O). ¹H NMR spectrum, δ , ppm: 2.45 (3H, s, COCH₃); 3.15 (3H, s, OCH₃); 7.41–7.63 (4H, m, Ar); 8.33 (1H, s, =CH); 9.50 (1H, br. s, NH). ¹³C NMR spectrum, δ , ppm: 24.1 (CH₃); 43.0 (COCH₃); 116.1, 118.3, 122.2, 126.1, 162.3, 174.4 (C=O). Mass spectrum, m/z (I_{rel} , %): 260 [M]⁺ (100), 229 (45), 218 (31), 155 (21). Found, %: C 60.21; H 4.83; N 14.75. C₁₃H₁₂N₂O₄. Calculated, %: C 60; H 4.65; N 10.76.

1-Acetyl-4-(4'-N,N-dimethylaminobenzylidene)-3,5-pyrazolidinedione (9d). Red needles from DMF-H₂O, 1:1. Yield 63%; mp 266–267°C. IR spectrum, ν , cm⁻¹: 3190 (NH), 1715, 1670 (C=O). ¹H NMR spectrum, δ , ppm: 2.51 (3H, s, COCH₃); 3.15 (6H, s, NCH₃); 7.12 (4H, m, Ar); 7.75 (1H, s, =CH); 8.51 (1H, br. s, NH). ¹³C NMR spectrum, δ , ppm: 39.1, 42.0, 121.2, 122.3, 125.1, 172.0. Mass spectrum, m/z (I_{rel} , %): 273 [M]⁺ (22), 258 (15), 231 (100), 229 (63), 155 (18). Found, %: C 61.72; H 5.72; N 15.42. C₁₄H₁₅N₃O₃. Calculated, %: C 61.53; H 5.53; N 15.38.

1-Acetyl-4-(4'-chlorobenzylidene)-3,5-pyrazolidinedione (9e). Colorless needles from methanol. Yield 61%; mp 160–161°C. IR spectrum, ν , cm⁻¹: 3120 (NH), 1710, 1680 (C=O). ¹H NMR spectrum, δ , ppm: 2.52 (3H, s, COCH₃); 7.31–7.52 (4H, m, Ar); 8.42 (1H, s, =CH); 9.42 (1H, s, NH). ¹³C NMR spectrum, δ , ppm: 21.1, 116.3, 123.1, 124.2, 162.1, 172.0. Mass spectrum, m/z (I_{rel} , %): 264 [M]⁺ (100), 231 (24), 222 (52), 153 (14). Found, %: C 54.62; H 3.52; Cl 13.32; N 10.66. C₁₂H₉ClN₂O₂. Calculated, %: C 54.46; H 3.43; Cl 13.40; N 10.58.

1-Acetyl-4-(4'-nitrobenzylidene)-3,5-pyrazolidinedione (9f). Pale-yellow needles from methanol. Yield 62%; mp 210–211°C. IR spectrum, ν , cm⁻¹: 3210 (NH), 1705, 1670 (C=O), 1550 (NO₂). ¹H NMR spectrum, δ , ppm: 2.51 (3H, s, COCH₃); 7.42–7.81 (4H, m, Ar); 8.32 (1H, s, =CH); 9.22 (1H, s, NH). ¹³C NMR spectrum, δ , ppm: 21.2, 114.1, 115.2, 116.1, 123.1, 165.4, 172.3. Mass spectrum, m/z (I_{rel} , %): 275 [M]⁺ (100), 259 (15), 233 (72), 229 (13). Found, %: C 52.44; H 3.25; N 15.18. C₁₂H₉N₃O₅. Calculated, %: C 52.37; H 3.30; N 15.27.

1-Acetyl-4-(3'-nitrobenzylidene)-3,5-pyrazolidinedione (9g). Brown needles from ethanol. Yield 68%; mp 206–207°C. IR spectrum, ν , cm⁻¹: 3120 (NH), 1710, 1680 (C=O), 1555 (NO₂). ¹H NMR spectrum, δ , ppm: 2.52 (3H, s, COCH₃); 7.32–7.61 (4H, m, Ar); 7.91 (1H, s, =CH); 9.15 (1H, s, NH). ¹³C NMR spectrum, δ , ppm: 22.3, 120.1, 126.2, 132.1, 165.1, 175.4. Found, %: C 52.47; H 3.44; N 15.33. C₁₂H₉N₃O₅. Calculated, %: C 52.37; H 3.30; N 15.27.

1-Acetyl-4-(4'-hydroxybenzylidene)-3,5-pyrazolidinedione (9h). Grayish needles from ethanol. Yield 86%; mp 250–251°C. IR spectrum, ν , cm⁻¹: 3600 (OH), 3250 (NH), 1705, 1660 (C=O). ¹H NMR spectrum, δ , ppm: 2.41 (3H, s, COCH₃); 6.92–7.77 (4H, m, Ar); 8.72 (1H, s, =CH); 10.63 (1H, s, NH). ¹³C NMR spectrum, δ , ppm: 25.1, 119.3, 124.0, 169.3, 170.2, 172.1. Mass spectrum, m/z (I_{rel} , %): 246 [M]⁺ (100).

Epoxidation of 4-alkylidene(arylidene)-3,5-pyrazolidinedione (6) (General Method). A suspension of the compound **5** derivative (0.01 mol) in hydrogen peroxide (30 volume, 5 ml) and ether (10 ml) was stirred until the color disappeared. The solid was filtered, washed with cold methanol, and crystallized from the proper solvent.

2,2-Dimethyl-1-oxa-5,6-diazaspiro[2,4]heptane-4,7-dione (10). Colorless plates from methanol. Yield 54%; mp 207–208°C. IR spectrum, ν , cm⁻¹: 3199 (NH), 1680 (C=O). ¹H NMR spectrum, δ , ppm: 1.51 (6H, s, CH₃); 13.25 (2H, s, 2NH). ¹³C NMR spectrum, δ , ppm: 18.1, 68.5, 58.6, 166.2. Mass spectrum, m/z (I_{rel} , %): 156 [M]⁺ (30), 116 (75), 70 (11), 69 (25), 59 (16), 58 (13), 45 (100), 44 (34), 43 (82), 42 (43), 41 (58). Found, %: C 46.22; H 5.22; N 18.1. C₆H₈N₂O₃. Calculated, %: C 46.15; H 5.16; N 17.94.

2,3-Dihydro-1H-dispiro[indole-3,2'-oxirane-3',4''-pyrazolidine]-2,3'',5''-trione (11). Yellow needles from ethanol. Yield 56%; mp 268–270°C. IR spectrum, ν , cm⁻¹: 3450 (OH), 3250 (NH), 1690 (C=O). ¹H NMR spectrum, δ , ppm: 6.93–7.57 (4H, m, Ar); 10.22 (2H, s, 2NH). ¹³C NMR spectrum, δ , ppm: 65.9, 90.3, 120.3, 124.3, 125.6, 128.2, 129.6, 137.7, 172.7, 174.8. Mass spectrum, m/z (I_{rel} , %): 245 [M]⁺ (100). Found, %: C 53.72; H 2.72; N 17.26. C₁₁H₇N₃O₄. Calculated, %: C 53.88; H 2.88; N 17.14.

Synthesis of 4-Arylazo-3,5-pyrazolidinediones 13 (General Method). The primary aromatic amine derivative (0.01 mol) was diazotized by dissolving in hydrochloric acid (2.5 mol) and the resulting solution was cooled in an ice-salt bath to -5°C, then the equivalent amount of sodium nitrite (0.01 mol) dissolved in water (5 ml) was added. The resulting diazonium salt was coupled with compound **5** (0.01 mol) dissolved in methanol (10 ml) and the mixture was neutralized with sodium acetate. The precipitated azo dye was filtered off, washed thoroughly with water, dried, and crystallized from the proper solvent.

4-Phenylazo-3,5-pyrazolidinedione (13a). Red needles from methanol. Yield 70%; mp 278-279°C. IR spectrum, ν , cm^{-1} : 3290, 3215 (NH), 1655 (C=O). ^1H NMR spectrum, δ , ppm: 3.52 (1H, s, CH); 7.44 (5H, m, Ar); 7.97 (2H, br. s, NH). ^{13}C NMR spectrum, δ , ppm: 80.6, 122.3, 125.0, 129.1, 170.3. Mass spectrum, m/z (I_{rel} , %): 204 $[\text{M}]^+$ (100), 197 (2), 194 (1.5), 176 (2), 169 (3), 145 (5.3), 127 (37), 107 (4), 105 (9), 93 (34), 92 (35), 78 (11), 77 (67), 64 (18), 65 (46.6). Found, %: C 53.12; H 4.21; N 27.36. $\text{C}_9\text{H}_8\text{N}_4\text{O}_2$. Calculated, %: C 52.94; H 3.95; N 27.44.

4-(4'-Methoxyphenylazo)-3,5-pyrazolidinedione (13b). Dark-red needles from methanol. Yield 43%; mp 230-231°C. IR spectrum, ν , cm^{-1} : 3450 (OH), 3350 (NH), 1640 (C=O). ^1H NMR spectrum, δ , ppm: 3.42 (1H, s, CH); 3.73 (3H, s, CH_3O); 6.91 (4H, m, Ar); 9.85 (2H, br. s, 2NH). ^{13}C NMR spectrum, δ , ppm: 56.0, 80.6, 114.6, 123.3, 143.2, 159.4, 170.3. Mass spectrum, m/z (I_{rel} , %): 234 $[\text{M}]^+$ (75), 197 (2), 175 (3), 149 (2), 147 (3), 123 (21), 122 (100), 121 (14), 108 (14), 107 (9), 95 (13), 60 (44), 45 (68), 43 (79). Found, %: C 51.36; H 4.25; N 22.82. $\text{C}_{10}\text{H}_{10}\text{N}_4\text{O}_3$. Calculated, %: C 51.28; H 4.30; N 23.92.

4-(2'-Nitrophenylazo)-3,5-pyrazolidinedione (13c). Red needles from methanol. Yield 80%; mp 309-310°C. IR spectrum, ν , cm^{-1} : 3400 (OH), 3250 (NH), 1665 (C=O), 1550 (NO_2). ^1H NMR spectrum, δ , ppm: 3.41 (1H, s, CH); 6.60 (4H, m, Ar); 9.23 (2H, s, NH). ^{13}C NMR spectrum, δ , ppm: 80.6, 115.9, 120.1, 123.3, 123.7, 143.8, 170.3. Mass spectrum, m/z (I_{rel} , %): 249 $[\text{M}]^+$ (20), 248 (100), 163 (21), 150 (5), 138 (39), 136 (10), 127 (71), 122 (16), 90 (12), 43 (37). Found, %: C 43.42; H 2.95; N 28.23. $\text{C}_9\text{H}_7\text{N}_5\text{O}_4$. Calculated, %: C 43.38; H 2.83; N 28.11.

4-(2'-Chlorophenylazo)-3,5-pyrazolidinedione (13d). Dark-red needles from methanol. Yield 84%; mp 280-281°C. IR spectrum, ν , cm^{-1} : 3100 (NH), 1665 (C=O). ^1H NMR spectrum, δ , ppm: 3.41 (1H, s, CH); 7.22 (4H, m, Ar); 9.62 (2H, s, 2NH). ^{13}C NMR spectrum, δ , ppm: 82.4, 115.1, 122.3, 124.1, 125.1, 144.3, 170.4. Mass spectrum, m/z (I_{rel} , %): 238 $[\text{M}]^+$ (100). Found, %: 45.41; H 3.15; Cl 14.75; N 23.53. $\text{C}_9\text{H}_7\text{ClN}_4\text{O}_2$. Calculated, %: C 45.30; H 2.96; Cl 14.86; N 23.48.

Synthesis of Diethyl Arylazomalonate 14 (General Method). The aryl diazonium salts were prepared by diazotization of the corresponding primary aromatic amines using sodium nitrite and hydrochloric acid. It was coupled with the equivalent amount of diethyl malonate and the mixture was neutralized using sodium acetate to give the required azo derivative. The dye was filtered off, washed with water, and dried.

Diethyl 2-Nitrophenylazomalonate (14a). Pale-yellow needles from ethanol. Yield 75%; mp 79-80°C. IR spectrum, ν , cm^{-1} : 1715 (C=O), 1525 (NO_2). ^1H NMR spectrum, δ , ppm (J , Hz): 1.26 (6H, t, $J = 6.7$, 2 CH_3); 3.32 (1H, s, CH); 4.21 (4H, q, $J = 6.7$, 2 CH_2); 7.51 (4H, m, Ar). ^{13}C NMR spectrum, δ , ppm: 22.1, 38.3, 54.0, 119.4, 123.2, 128.1, 171.4. Mass spectrum, m/z (I_{rel} , %): 309 $[\text{M}]^+$ (100). Found, %: C 50.52; H 4.72; N 13.65. $\text{C}_{13}\text{H}_{15}\text{N}_3\text{O}_6$. Calculated, %: C 50.49; H 4.89; N 13.59.

Diethyl 2-Chlorophenylazomalonate (14b). Yellow needles from ethanol. Yield 73%; mp 60-61°C. IR spectrum, ν , cm^{-1} : 1710 (C=O). ^1H NMR spectrum, δ , ppm (J , Hz): 1.26 (6H, t, $J = 6.4$, 2 CH_3); 3.32 (1H, s, CH); 4.25 (4H, q, $J = 6.4$, 2 CH_2); 7.62 (4H, m, Ar). ^{13}C NMR spectrum, δ , ppm: 21.3, 38.1, 53.1, 122.0, 124.4, 130.2, 169.3. Mass spectrum, m/z (I_{rel} , %): 298 $[\text{M}]^+$ (43), 297 (69), 254 (11), 225 (35), 223 (79), 153 (18), 128 (21), 127 (61), 126 (60), 125 (100), 113 (15), 111 (38), 99 (56). Found, %: C 52.41; H 5.12; Cl 11.83; N 9.35. $\text{C}_{13}\text{H}_{15}\text{ClN}_2\text{O}_4$. Calculated, %: C 52.27; H 5.06; Cl 11.87; N 9.38.

Synthesis of Arylazomalononic Acid Hydrazides (15) (General Method). The arylazo diethyl malonate (0.01 mol) was dissolved in absolute ethanol (20 ml), the solution was treated with hydrazine hydrate (0.03 mol), and the mixture was stirred for 2 h. The precipitated product was filtered off, washed with water, and dried. It was crystallized from the proper solvent.

2-Nitrophenylazomalononic Acid Hydrazide (15a). Pale-yellow needles from methanol. Yield 98%; mp 258-259°C. IR spectrum, ν , cm^{-1} : 3450, 3200 (NH_2 , NH), 1650 (C=O). ^1H NMR spectrum, δ , ppm: 2.51 (1H, s, CH); 7.93 (4H, m, Ar); 9.81 (4H, s, 2 NH_2); 13.76 (2H, br. s, 2NH). ^{13}C NMR spectrum, δ , ppm: 38.2, 122.1, 124.3, 136.1, 172.1. Mass spectrum, m/z (I_{rel} , %): 281 $[\text{M}]^+$ (100). Found, %: C 38.51; H 4.01; N 34.77. $\text{C}_9\text{H}_{11}\text{N}_7\text{O}_4$. Calculated, %: C 38.44; H 3.94; N 34.86.

2-Chlorophenylazomalic Acid Hydrazide (15b). Yellow needles from methanol. Yield 98%; mp 221–222°C. IR spectrum, ν , cm^{-1} : 3300, 3200 (NH_2 , NH), 1660 ($\text{C}=\text{O}$). ^1H NMR spectrum, δ , ppm: 3.12 (1H, s, CH); 6.91–7.35 (4H, m, Ar); 9.43 (4H, s, 2NH_2); 10.62 (2H, s, NH). ^{13}C NMR spectrum, δ , ppm: 39.2, 118.1, 123.0, 130.2, 175.2. Mass spectrum, m/z (I_{rel} , %): 270 [M] $^+$ (74), 238 (40), 152 (9), 139 (18), 129 (17), 128 (27), 127 (58), 126 (64), 125 (13), 111 (35), 40 (13), 32 (100). Found, %: C 40.12; H 4.15; Cl 13.22; N 31.16. $\text{C}_9\text{H}_{11}\text{ClN}_6\text{O}_2$. Calculated, %: C 39.94; H 4.10; Cl 13.10; N 31.05.

Synthesis of 1-Acetyl-4-arylazo-3,5-pyrazolidinediones 16 (General Method). Arylazo malonic acid hydrazide **15** (0.1 mol) was refluxed in glacial acetic acid for 2 h. The reaction mixture was poured on ice-water and the resulting product was filtered off, washed with water, and dried. The pyrazolidinedione derivative was crystallized from the proper solvent and the results are summarized as follows:

1-Acetyl-4-(2'-nitrophenylazo)-3,5-pyrazolidinedione (16a). Yellow needles from methanol. Yield 75%; mp 309–310°C. IR spectrum, ν , cm^{-1} : 1690 ($\text{C}=\text{O}$), 1550 (NO_2). ^1H NMR spectrum, δ , ppm: 2.52 (3H, s, COCH_3); 3.12 (1H, s, CH); 7.54–8.22 (4H, m, Ar); 9.42 (1H, br. s, NH). ^{13}C NMR spectrum, δ , ppm: 22.1, 112.0, 114.3, 118.2, 122.1, 162.4, 170.1. Mass spectrum, m/z (I_{rel} , %): 291 [M] $^+$ (2), 249 (100), 190 (5), 189 (6), 173 (20), 163 (13), 138 (21), 127 (47), 122 (11). Found, %: C 45.42; H 3.12; N 14.14. $\text{C}_{11}\text{H}_9\text{N}_5\text{O}_5$. Calculated, %: C 45.37; H 3.11; N 14.05.

1-Acetyl-4-(2'-chlorophenylazo)-3,5-pyrazolidinedione (16b). Yellow needles from methanol. Yield 75%; 280–281°C. IR spectrum, ν , cm^{-1} : 3200 (NH), 1690 ($\text{C}=\text{O}$). ^1H NMR spectrum, δ , ppm: 2.51 (3H, s, COCH_3); 3.21 (1H, s, CH); 7.22–7.80 (4H, m, Ar); 9.32 (1H, br. s, NH). ^{13}C NMR spectrum, δ , ppm: 22.0, 39.2, 118.2, 122.4, 126.1, 164.2, 175.4. Mass spectrum, m/z (I_{rel} , %): 238 [M] $^+$ (90), 237 (12), 202 (29), 153 (13), 151 (38), 139 (12), 128 (26), 127 (100), 126 (65), 125 (32), 111 (39), 101 (18), 99 (50), 69 (23). Found, %: C 47.22; H 3.35; Cl 12.58; N 20.14. $\text{C}_{11}\text{H}_9\text{ClN}_4\text{O}_3$. Calculated, %: C 47.07; H 3.23; Cl 12.63; N 19.96.

Reduction of 4-Arylidene-3,5-pyrazolidinediones. Synthesis of 4-Benzyl-3,5-pyrazolidinediones (General Method). A suspension of the 3,5-pyrazolidinedione derivative **6** (0.01 mol) in methanol (10 ml) was refluxed with an aqueous solution of sodium borohydride (0.02 mol in 10 ml water) for 2 h. The reaction mixture was cooled to room temperature and neutralized with diluted hydrochloric acid. The precipitated solid was collected, washed thoroughly with water, and dried. It was crystallized from the proper solvent.

4-(4'-N,N-Dimethylaminobenzyl)-3,5-pyrazolidinedione (17). Grayish needles from dioxane. Yield 30%; mp 220–221°C. IR spectrum, ν , cm^{-1} : 3410 (broad, OH, NH), 1655 ($\text{C}=\text{O}$). ^1H NMR spectrum, δ , ppm (J , Hz): 2.85 (6H, s, 2CH_3); 2.91 (2H, d, $J = 6.3$, CH_2); 3.21 (1H, t, $J = 6.3$, CH); 6.72–7.53 (4H, m, Ar); 7.62 (2H, br. s, 2NH). ^{13}C NMR spectrum, δ , ppm: 28.7, 43.6, 66.1, 113.3, 128.8, 129.7, 141.7, 172.1. Mass spectrum, m/z (I_{rel} , %): 233 [M] $^+$ (100). Found, %: C 61.78; H 6.51; N 18.14. $\text{C}_{12}\text{H}_{15}\text{N}_3\text{O}_2$. Calculated, %: C 61.79; H 6.48; N 18.01.

1-Acetyl-4-(4'-nitrobenzyl)-3,5-pyrazolidinedione (18). Pale-brown needles from dioxane. Yield 31%; mp 238–239°C. IR spectrum, ν , cm^{-1} : 3200 (NH), 1680 ($\text{C}=\text{O}$), 1520 (NO_2). ^1H NMR spectrum, δ , ppm (J , Hz): 2.41 (3H, s, CH_3); 3.07 (2H, d, $J = 6.4$, CH_2); 3.76 (1H, t, $J = 6.4$, CH); 7.62–8.33 (4H, m, Ar); 8.91 (1H, br. s, NH). ^{13}C NMR spectrum, δ , ppm: 21.1, 43.3, 58.2, 116.1, 122.0, 124.3, 126.1, 175.2. Found, %: C 52.12; H 3.92; N 15.23. $\text{C}_{12}\text{H}_{11}\text{N}_3\text{O}_5$. Calculated, %: C 51.99; H 4.00; N 15.16.

X-ray Analysis. X-ray crystal-structure determinations for compounds **6a,e** and **10** (Table 1 and Fig. 1a,c). All measurements were conducted on a Nonius KappaCCD area detector diffractometer [41] using graphite-monochromated $\text{MoK}\alpha$ radiation (λ 0.71073 Å) and an Oxford Cryosystems Cryostream 700 cooler. Data reduction was performed with HKLDENZO and SCALEPACK [42]. The intensities were corrected for Lorentz and polarization effects, but not for absorption, and equivalent reflections were merged. Each structure was solved by direct methods using either SHELXL97 [43] or SIR92 [44], which revealed the positions of all non-hydrogen atoms. The non-hydrogen atoms of each structure were refined anisotropically. The amide H-atoms were placed in the positions indicated by a difference electron density map and their positions were allowed to refine together with individual isotropic displacement parameters. All remaining H-atoms were placed in

geometrically calculated positions and refined using a riding model where each H-atom was assigned a fixed isotropic displacement parameter with a value equal to $1.2 U_{\text{eq}}$ of its parent C-atom ($1.5 U_{\text{eq}}$ for methyl groups). The structures were refined on F^2 using full-matrix least-squares procedures, which minimized the function $\Sigma w(F_o^2 - F_c^2)^2$. A correction for secondary extinction was applied in the case of compound **6e**. For compound **10** one low-angle reflection were omitted from the final refinement because the observed intensities of this reflection was much lower than the calculated value as a result of being partially obscured by the beam slope. Neutral atom scattering factors for non-hydrogen atoms were taken from [45], and the scattering factors for H-atoms were taken from [46]. The values of the mass attenuation coefficients were those of [47]. All calculations were performed using SHELXL97 [43]. The crystallographic diagrams were drawn using ORTEPII [48]. CCDC-750291-750293, contain the supplementary crystallographic data for this paper. These data can be obtained free of charge from the Cambridge crystallographic data centre *via* www.ccdc.cam.ac.uk/data-request/cif.

The authors are grateful to Dr. Anthony Linden, Institute of Organic Chemistry, University of Zurich for conducting the three crystal structure determinations.

REFERENCES

1. A. Hemming and W. C. Kuzell, *Antibiot. Chemother.*, **3**, 634 (1953).
2. J. Paul, J. R. Duncan, P. Sharp, A. Norris, M. A. Siddiq, and C. Bacon, *Clin. Infect. Dis.*, **40**, 1859 (2005).
3. M. A. Virji, S. T. Venkataraman, D. R. Lower, and K. N. Rao, *J. Toxicol., Clin. Toxicol.*, **41**, 1013 (2003).
4. T. Miura, S. Muraoka, and Y. Fujimoto, *Life Sci.*, **70**, 2611 (2002).
5. M. Bigby and R. Stern, *J. Am. Acad. Dermatol.*, **12**, 866 (1985).
6. L. Marmasse, *Phlebologie*, **28**, 75 (1975).
7. V. Uchaipichat, P. I. Machenzie, D. J. Elliot, and J. O. Miners, *Drug Metab. Dispos.*, **34**, 449 (2006).
8. S. Muraoka and T. Miura, *Basic Clin. Pharmacol. Toxicol.*, **99**, 261 (2006).
9. T. Nishiyama, T. Kobori, K. Arai, K. Ogura, T. Ohnuma, K. Ishii, K. Hayashi, and A. Hiratsuka, *Arch. Biochem. Biophys.*, **454**, 72 (2006).
10. K. Moribe, S. Tsutsumi, S. Morishita, H. Shinozaki, Y. Tozuka, T. Oguchi, and K. Yamamoto, *Chem. Pharm. Bull.*, **53**, 1025 (2005).
11. J. F. Arens and O. S. Tiang, *Indonesia J. Nat. Sci.*, **109**, 215 (1953).
12. V. V. Feofilaktov, *Bull. Acad. Sci. USSR, Classe Sci. Chim.*, 521 (1941); *Chem. Abstr.*, **37**, 2347.
13. H. N. Rydon and S. Siddappas, *J. Chem. Soc.*, 2462 (1951).
14. H. Yasuda, *Rep. Sci. Res. Inst. (Japan)*, **30**, 340 (1954).
15. J. D. Kendall and D. J. Fry, Brit Pat. 585781 (1947); *Chem. Abstr.*, **42**, 472 (1948)
16. J. D. Kendall and D. J. Fry, US Pat. 2457823 (1949); *Chem. Abstr.*, **43**, 8149 (1949).
17. E. Sudo, *J. Chem. Soc. Jpn. Pure Chem. Sect.*, **74**, 658 (1953); *Chem. Abstr.*, **48**, 2510 (1954).
18. V. P. Zhivopistsev, *Dokl. Akad. Nauk SSSR*, **73**, 1193 (1950).
19. V. P. Zhivopistsev, *Zh. Prikl. Khim.*, **26**, 355 (1953).
20. M. E. Fradette, C. Celestec, H. Richard, G. Beauchamp, and S. Lavetry, *Am. J. Vet. Res.*, **68**, 128 (2007).
21. S. K. Reed, N. T. Messer, R. K. Tessman, and G. Keegank, *Am. J. Vet. Res.*, **67**, 398 (2006).
22. C. Beretta, G. Garavaglia, and M. Cavalli, *Pharmacol. Res.*, **52**, 302 (2005).
23. P. G. Jones, *Vet. Rec.*, **156**, 554 (2005).

24. L. Monreal, D. Sabate, D. Segura, I. Mayos, and J. Homedes, *Res. Vet. Sci.*, **76**, 145 (2004).
25. P. L. Chamberlain, B. A. Fowler, M. J. Sexton, J. O. Peggins, and J. Bredow, *Toxicol. Appl. Pharmacol.*, **187**, 198 (2003).
26. A. K. Arkfah and P. Lees, *J. Vet. Pharmacol. Ther.*, **25**, 299 (2002).
27. M. I. Gonzáles Martín, C. I. Sanchez Gonzáles, A. Jimenez Hernandez, M. D. Garcia Cachan, M. J. Gastro de Cabo, and A. L. Garzon Cuadrado, *J. Chromatogr. B*, **769**, 119 (2002).
28. N. S. Mathews, K. E. Peck, T. S. Taylor, and K. L. Mealey, *Am. J. Vet. Res.*, **62**, 673 (2001).
29. F. K. Reilly, *Am. J. Vet. Res.*, **61**, 728 (2000).
30. M. E. Houch, C. M. Steel, J. R. Bolton, and J. V. Vovich, *Aust. Vet.*, **77**, 785 (1999).
31. S. Pyörälä, T. Laurila, S. Lehtonen, S. Leppä, and L. Kaartinen, *Acta Vet. Scand.*, **40**, 145 (1999).
32. A. D. Barth and M. R. Wood, *Can. Vet. J.*, **39**, 103 (1998).
33. W. M. Zweers-Zeilmaker, G. J. Horbach, and R. F. Witkamp, *Xenobiotica*, **27**, 769 (1997).
34. M. Rackallio, P. M. Taylor, and R. C. Bennett, *Vet. Surg.*, **26**, 150 (1997).
35. G. Fritsch, G. Zinner, M. Beimel, D. Mootz, and H. Wunderlich, *Arch. Pharm.*, **319**, 70 (1986).
36. T. Curtius, *J. Prakt. Chem.*, **125**, 211 (1930).
37. A. Charaibi, C. Luu-Duc, and J. Chantegrel, *Pharm. Franc.*, **41**, 45 (1983).
38. G. B. Oayne and P. H. Williams, *J. Org. Chem.*, **26**, 651 (1961).
39. A. Hasner and C. Heathcock, *J. Org. Chem.*, **29**, 1350 (1964).
40. S. Ruhemann, *Ber.*, **27**, 1658 (1894).
41. R. Hooft, KappaCCD Collect Software, Nonius BV, Delft, The Netherlands, 1999.
42. Z. Otwinowski and W. Minor, in: Pt. A, C. W. Carter Jr., R. M. Sweet (editors), *Methods in Enzymology*, Vol. 276, *Macromolecular Crystallography*, Academic Press, New York, 1997, p. 307.
43. G. M. Sheldrick, *SHELXS97, Program for the Solution of Crystal Structures*, Univ. of Göttingen, Germany (1997).
44. A. Altomare, G. Cascarano, C. Giacovazzo, A. Guagliardi, M. C. Burla, G. Polidori, and M. Camalli, *J. Appl. Crystallogr.*, **27**, 435 (1994).
45. E. N. Maslen, A. G. Fox, and M. A. O'Keefe, in: A. J. C. Wilson (editor), *International Tables for Crystallography*, Kluwer, Dordrecht, Vol. C, Table 6.1.1.1, 1992, p. 477.
46. R. F. Stewart, E. R. Davidson, and W. T. Simpson, *J. Chem. Phys.*, **42**, 3175 (1965).
47. D. C. Creagh, J. H. Hubbell, in: A. J. C. Wilson (editor), *International Tables for Crystallography*, Kluwer, Dordrecht, Vol. C, Table 4.2.4.3, 1992, p. 200.
48. C. K. Johnson, *ORTEPII, Report ORNL-5138*, Oak Ridge National Laboratory, Oak Ridge, Tennessee, 1976.